My ePortfolio Register   

AACR 2017 /
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours

1st - 5th Apr 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.04.17
Views: 1121

Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Hyman presents data from the SUMMIT trial at a press conference at AACR 2017, in which patients with solid tumours displaying mutations in HER2 or HER3 were treated with neratinib, and their response assessed.

He describes positive responses in HER2 mutant breast cancer, cervical cancer and biliary cancer, though notes a lack of activity in bladder colorectal cancer and all solid tumours with HER3 mutations.

To view the slides from this presentation, click here.

Dr Hyman discussed these results further with ecancer here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence